These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32416986)

  • 1. Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
    Mukherjee N; Panda CK
    Clin Breast Cancer; 2020 Oct; 20(5):361-370. PubMed ID: 32416986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
    Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
    PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Wnt/β-catenin signaling pathway in cancer.
    Zhang Y; Wang X
    J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumacaftor as a potential repurposed drug in targeting breast cancer stem cells: insights from in silico study.
    Pathak Y; Camps I; Yadav M; Mishra A; Upadhyay J; Tripathi V
    J Mol Model; 2024 Jun; 30(7):227. PubMed ID: 38913211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
    Cheng X; Xu X; Chen D; Zhao F; Wang W
    Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
    Vilchez V; Turcios L; Marti F; Gedaly R
    World J Gastroenterol; 2016 Jan; 22(2):823-32. PubMed ID: 26811628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.
    Prosperi JR; Goss KH
    Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt/beta-catenin pathway: modulating anticancer immune response.
    Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
    J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
    Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
    Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Wnt/β-catenin signal pathway for the treatment of gastrointestinal cancer: Potential for advancement.
    Jin X; Wang S; Luo L; Yan F; He Q
    Biochem Pharmacol; 2024 Sep; 227():116463. PubMed ID: 39102994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganoderma lucidum (Reishi) suppresses proliferation and migration of breast cancer cells via inhibiting Wnt/β-catenin signaling.
    Zhang Y
    Biochem Biophys Res Commun; 2017 Jul; 488(4):679-684. PubMed ID: 28427938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.
    Wang Z; Li B; Zhou L; Yu S; Su Z; Song J; Sun Q; Sha O; Wang X; Jiang W; Willert K; Wei L; Carson DA; Lu D
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13150-13155. PubMed ID: 27799526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diallyl Trisulfide inhibits breast cancer stem cells via suppression of Wnt/β-catenin pathway.
    Li X; Meng Y; Xie C; Zhu J; Wang X; Li Y; Geng S; Wu J; Zhong C; Li M
    J Cell Biochem; 2018 May; 119(5):4134-4141. PubMed ID: 29243835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
    Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
    Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of targeting Wnt/β-catenin in colon cancer.
    Sebio A; Kahn M; Lenz HJ
    Expert Opin Ther Targets; 2014 Jun; 18(6):611-5. PubMed ID: 24702624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation.
    Raut D; Vora A; Bhatt LK
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):97-114. PubMed ID: 34927527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
    Dzobo K; Thomford NE; Senthebane DA
    OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.
    Krishnamurthy N; Kurzrock R
    Cancer Treat Rev; 2018 Jan; 62():50-60. PubMed ID: 29169144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy.
    Song P; Gao Z; Bao Y; Chen L; Huang Y; Liu Y; Dong Q; Wei X
    J Hematol Oncol; 2024 Jun; 17(1):46. PubMed ID: 38886806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfur-Coordinated Organoiridium(III) Complexes Exert Breast Anticancer Activity via Inhibition of Wnt/β-Catenin Signaling.
    Sun Q; Wang Y; Fu Q; Ouyang A; Liu S; Wang Z; Su Z; Song J; Zhang Q; Zhang P; Lu D
    Angew Chem Int Ed Engl; 2021 Feb; 60(9):4841-4848. PubMed ID: 33244858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.